Core Viewpoint - Labcorp's shares have increased by approximately 2.5% since the last earnings report, which is underperforming compared to the S&P 500 [1] Group 1: Earnings and Estimates - Recent estimates for Labcorp have trended downward over the past month [2] - The magnitude of estimate revisions for Labcorp has been net zero, indicating stability in expectations [4] Group 2: VGM Scores and Rankings - Labcorp has a subpar Growth Score of D and a similar score for momentum, but a B grade for value, placing it in the top 40% for this investment strategy [3] - The overall VGM Score for Labcorp is C, which is relevant for investors not focused on a single strategy [3] - Labcorp holds a Zacks Rank of 3 (Hold), suggesting an expectation of an in-line return in the coming months [4] Group 3: Industry Performance - Labcorp is part of the Zacks Medical - Dental Supplies industry, where West Pharmaceutical Services has seen a slight gain of 0.1% over the past month [5] - West Pharmaceutical reported revenues of $698 million for the last quarter, reflecting a year-over-year increase of 0.4% [5] - The expected earnings for West Pharmaceutical for the current quarter is $1.51 per share, indicating a year-over-year decline of 0.7% [6]

Company Overview - Snap's shares have increased by approximately 4.8% over the past month, underperforming the S&P 500 index [1] - Recent earnings report indicates a need to analyze catalysts affecting Snap's performance [1] Earnings Estimates - Fresh estimates for Snap have trended downward, with the consensus estimate shifting by -34.58% [2] VGM Scores - Snap has a Growth Score of A, but a Momentum Score of F, and a Value Score of F, placing it in the lowest quintile for value investment strategy [3] - The overall aggregate VGM Score for Snap is C, which is relevant for investors not focused on a single strategy [3] Outlook - The downward trend in estimates suggests a negative outlook for Snap, with a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [4] Industry Comparison - Snap is part of the Zacks Internet - Software industry, where F5 Networks has seen a 7% increase in the past month [5] - F5 reported revenues of $731.12 million for the last quarter, reflecting a year-over-year growth of +7.3% and an EPS of $3.42 compared to $2.91 a year ago [5] - F5 is projected to post earnings of $3.49 per share for the current quarter, with a year-over-year change of +3.9% and a Zacks Consensus Estimate change of -0.8% over the last 30 days [6] - F5 holds a Zacks Rank of 2 (Buy) based on the direction and magnitude of estimate revisions, along with a VGM Score of C [6]

Core Viewpoint - The economic indicators for May 2025 show a slight recovery, with the BCI reading at 50.3, indicating stabilization in the economy due to a combination of financial policies and tariff reductions, although the trend still requires consolidation [1][2][18]. Economic Indicators - The BCI reading for May 2025 is 50.3, up 0.2 points from the previous value, reflecting a recovery in economic conditions since the "9·24" event [2]. - The BCI readings from October 2024 to May 2025 show fluctuations: 46.0 in September 2024, rising to 50.5 in November 2024, then dipping to 48.3 in December 2024, and reaching 54.8 in March 2025 before a slight decline to 50.1 in April 2025 [2]. Microeconomic Conditions - The microeconomic indicators show mixed results: improvements in financing environment, employment, and consumer price expectations, while declines are noted in intermediate goods price expectations, profit expectations, and investment expectations [4]. - The financing environment index improved to 49.1 in April, up from 48.0, indicating a better financing situation influenced by recent financial policies [4]. Employment Trends - Employment rebounded significantly in May, with the enterprise hiring index rising by 1.9 points, suggesting a high elasticity of employment in the external demand supply chain [9]. - The report estimates that foreign trade directly and indirectly supports around 170 million jobs, accounting for over 20% of total employment in the country [9]. Price Indicators - There is a divergence in price indicators: the consumer price expectation index is rising, while the intermediate goods price expectation index is declining, indicating pressure on industrial prices despite improvements in consumer prices [12]. - The profit expectation index continues to decline, reflecting ongoing pressure from low industrial prices, with PPI showing negative growth from January to April 2025 [14]. Investment Sentiment - The enterprise investment expectation index is declining, attributed to uncertainties in external environments and high real interest rates [15]. - Recommendations include lowering nominal interest rates and increasing government investment to stimulate corporate investment [15][16]. Conclusion - The economic situation in May shows improvement compared to April, but the trend needs further consolidation, with key factors such as US-China trade negotiations and local government project accelerations being crucial for future pricing [17][18].

Core Viewpoint - AutoZone, Inc. is expected to report its third-quarter fiscal 2025 results on May 27, with earnings per share (EPS) estimated at $36.78 and revenues at $4.4 billion, reflecting a 0.25% growth year-over-year [1][2]. Financial Performance - The Zacks Consensus Estimate for AutoZone's quarterly revenues indicates a year-over-year growth of 3.95% [2]. - In the second quarter of fiscal 2025, AutoZone's adjusted EPS was $28.29, missing the consensus estimate of $29.16 and decreasing from $28.89 in the prior year. Net sales were reported at $3.95 billion, missing the estimate of $3.99 billion but showing a 2.4% increase year-over-year [2]. Growth Prospects - AutoZone has achieved record sales for 35 consecutive years, with fiscal 2024 revenues of $18.5 billion, representing a 5.7% year-over-year increase. The company anticipates continued growth in fiscal 2025, driven by strong DIY and commercial business performance, with same-store sales growth expected to be 1.3% in the fiscal third quarter [3][5]. - The expansion of mega hubs is enhancing AutoZone's market penetration, with 111 mega hub locations established by the end of the second quarter of fiscal 2025. The company plans to open at least 19 more locations in the latter half of fiscal 2025 and around 100 international stores [4]. Earnings Expectations - The company's earnings model suggests a potential earnings beat for the upcoming quarter, supported by a positive Earnings ESP of +0.28% and a Zacks Rank of 3 (Hold) [6][7].

Core Viewpoint - Xiaopeng Motors aims to double its sales by 2025 and expects to achieve profitability in Q4 of the same year, with a positive free cash flow for the entire year [1] Group 1 - The company is confident in achieving over 100% year-on-year sales growth by 2025 [1] - The expectation for profitability in Q4 indicates a positive shift in the company's financial performance [1] - The goal of reaching positive free cash flow for the entire year suggests a focus on sustainable financial health [1]

Group 1: Company Performance - United Natural Foods (UNFI) shares increased by 7.6% to close at $30.57, with notable trading volume compared to typical sessions, and a total gain of 17.3% over the past four weeks [1][2] - The stock's rise is driven by optimism regarding its wholesale segment, new business from existing and newly acquired customers, and the impact of inflation, alongside a focus on lean management and operational efficiency [2] - The company is expected to report quarterly earnings of $0.23 per share, reflecting a year-over-year increase of 130%, with revenues projected at $7.82 billion, up 4.2% from the previous year [3] Group 2: Earnings Estimates and Market Position - The consensus EPS estimate for UNFI has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - UNFI currently holds a Zacks Rank of 3 (Hold), while another company in the same industry, Campbell's (CPB), has a Zacks Rank of 4 (Sell) and reported a 1.9% increase in its last trading session [4][5] - Campbell's EPS estimate for the upcoming report is $0.65, which is a decrease of 13.3% from the previous year [5]

Group 1 - Gossamer Bio reported a quarterly loss of $0.16 per share, better than the Zacks Consensus Estimate of a loss of $0.18, and an improvement from a loss of $0.19 per share a year ago, resulting in an earnings surprise of 11.11% [1] - The company achieved revenues of $9.89 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 167.27%, compared to zero revenues a year ago [2] - Gossamer Bio shares have increased approximately 11.7% since the beginning of the year, outperforming the S&P 500's gain of 0.2% [3] Group 2 - The earnings outlook for Gossamer Bio is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.18 on revenues of $4.13 million, and -$0.66 on revenues of $26.3 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Gossamer Bio belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] Group 3 - Gossamer Bio has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] - The estimate revisions trend for Gossamer Bio is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Company Performance - Star Bulk Carriers reported a quarterly loss of $0.07 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.23, and down from earnings of $0.87 per share a year ago, indicating an earnings surprise of 69.57% [1] - The company posted revenues of $230.65 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 9.56%, but down from $259.39 million in the same quarter last year [2] - Over the last four quarters, Star Bulk Carriers has surpassed consensus revenue estimates four times, but has only exceeded consensus EPS estimates once [2] Stock Performance - Star Bulk Carriers shares have increased approximately 9.9% since the beginning of the year, outperforming the S&P 500, which gained only 0.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $276.4 million, and for the current fiscal year, it is $1.31 on revenues of $1.05 billion [7] Industry Outlook - The Transportation - Shipping industry, to which Star Bulk Carriers belongs, is currently ranked in the bottom 19% of over 250 Zacks industries, indicating potential challenges ahead [8] - The outlook for the industry can significantly impact the stock's performance, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Allurion Technologies, Inc. reported a quarterly earnings of $0.43 per share, significantly beating the Zacks Consensus Estimate of a loss of $1.53 per share, marking an earnings surprise of 128.10% [1] Financial Performance - The company posted revenues of $5.58 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.11%, and a decline from $9.39 million in the same quarter last year [2] - Over the last four quarters, Allurion has surpassed consensus EPS estimates two times but has not beaten consensus revenue estimates [2] Stock Performance - Allurion shares have declined approximately 78.1% since the beginning of the year, contrasting with the S&P 500's gain of 0.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.15 on revenues of $6.05 million, and for the current fiscal year, it is -$4.19 on revenues of $28.6 million [7] Industry Outlook - The Medical - Products industry, to which Allurion belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Allurion's stock performance [5]

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non- re ...